<DOC>
	<DOCNO>NCT02130557</DOCNO>
	<brief_summary>Phase 3 , 2-arm , randomize , open label trial . Patients randomize receive bosutinib imatinib duration study .</brief_summary>
	<brief_title>A Multicenter Phase 3 , Open-Label Study Bosutinib Versus Imatinib Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>The study open enrollment plan number approximately 500 Philadelphia Chromosome Positive ( Ph+ ) patient randomize ( approximately 250 Ph+ patient treatment arm ; total approximately 530 Ph+ Ph- patient ) . All patient treat and/or follow approximately 5 year ( 240 week ) randomization study close . Patients discontinue study therapy early due disease progression intolerance study medication continue follow yearly survival approximately 5 year ( 240 week ) randomization .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>1 . Molecular diagnosis CP CML ≤ 6 month ( initial diagnosis ) . 2 . Adequate hepatic , renal pancreatic function . 3 . Age ≥ 18 year . 1 . Any prior medical treatment CML , include tyrosine kinase inhibitor ( TKIs ) , exception hydroxyurea and/or anagrelide treatment , permit 6 month prior study entry ( signature ICF ) suitably approve use subject 's region . 2 . Any past current Central Nervous System ( CNS ) involvement , include leptomeningeal leukemia . 3 . Extramedullary disease . 4 . Major surgery radiotherapy within 14 day randomization . 5 . History clinically significant uncontrolled cardiac disease . 6 . Known seropositivity human immunodeficiency virus ( HIV ) , current acute chronic hepatitis B ( hepatitis B surfaceantigen positive ) , hepatitis C , cirrhosis evidence decompensated liver disease . Patients resolve Hepatitis B include . 7 . Recent ongoing clinically significant GI disorder , e.g . Crohn 's Disease , Ulcerative Colitis , prior total partial gastrectomy . 8 . History another malignancy within 5 year exception basal cell carcinoma cervical carcinoma situ stage 1 2 cancer consider adequately treat currently complete remission least l2 month . 9 . Current , recent ( within 30 day , 5 halflives investigational product ) participation clinical trial investigational agent and/or contain interventional procedure deem contrary objective conduct trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myelogenous</keyword>
	<keyword>Chronic</keyword>
	<keyword>BCR-ABL Positive</keyword>
	<keyword>Bosutinib</keyword>
	<keyword>Leukemia , Myeloid</keyword>
	<keyword>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</keyword>
	<keyword>Philadelphia Chromosome</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Translocation , Genetic</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
</DOC>